Synthon sells generics company to BC Partners

June 30, 2019

De Brauw acted as lead counsel to Synthon Holding B.V.  a leading company in both the biopharmaceutical and generics pharmaceutical business based in Nijmegen, who sold its generics pharmaceutical business, Synthon International Holding B.V. to funds controlled by private equity firm BC Partners LLP.

De Brauw also advised both the Synthon and its Management board on their respective re-investments in the Company post-closing. Synthon will stay involved in the generics pharmaceutical business as a minority shareholder, but the sale brought Synthon to a position where they can focus more on the biopharmaceutical business. Signing of the transaction took place on Sunday 30 June 2019. Both Synthon and the Management team are very happy with the services provided by De Brauw not just on the transaction but also for the personal advice and support given throughout the deal.


Click here to read more about this deal.


De Brauw team: Arne Grimme, Lennard Keijzer, Yi Duan, Lindie Foord, Annelieke Anbeek, Thyla Fontein, Henk van Ravenhorst, Mark Rebergen, Barbara Kloppert, Oscar Lamme, Bart de Rijke, Claudia Priem-van Rappard, Erica Teeuwen and Glenn Klijn.

We keep track of you on our site with cookies, in order to offer the basic functionality of the website and generate user statistics on an anonymous basis to make our website more user-friendly. We do not use or share your data with third parties for advertising purposes.